CYTEK BIOSCIENCES, INC. The addition of the Tonbo Biosciences portfolio of reagents will enable Cytek to offer extended flow cytometry capabilities to meet customer needs in protein and cell analysis research. Tonbo’s reagents will complement Cytek’s cFluor® family of proprietary reagents, which represent the culmination of years of experience understanding full spectrum cytometry and how fluorophores react together in multicolor panels.
“Tonbo’s reagents meet the highest standards of quality and performance, making them a natural fit with our comprehensive suite of solutions for the cell analysis market," said Dr.
About
Other than Cytek’s Northern Lights CLC system, which is available for clinical use in
Cytek, Tonbo Biosciences, cFluor, Full Spectrum Profiling, FSP and Northern Lights are trademarks or registered trademarks of
In addition to filings with the
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible” and similar expressions, but the absence of such words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding Cytek’s expectations regarding its ability to offer extended flow cytometry capabilities to meet customer needs in protein and cell analysis research; the complementary fit of Tonbo’s reagents with Cytek’s cFluor® family of proprietary reagents; the fit of Tonbo’s reagents with Cytek’s comprehensive suite of solutions for the cell analysis market; Cytek’s ability to redefine possibilities in flow cytometry; and Cytek’s ability to offer a total solution to its customers. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management and involve risks that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties relating to the acquisition, such as Cytek’s lack of experience in acquiring and integrating new businesses; risks relating to the integration of Tonbo Biosciences’ business and operations with those of Cytek; the possibility that Cytek will not realize anticipated revenue and potential operating expense synergies from the acquisition; the possible loss of key employees, customers, or suppliers as a result of the acquisition; and risks relating to maintaining material in-licensed intellectual property rights and risks and uncertainties relating to Cytek’s ability to manage the growth and complexity of its organization and market conditions, including any impact of the ongoing COVID-19 pandemic. You should refer to the section entitled “Risk Factors” set forth in Cytek’s Quarterly Report on Form 10-Q for the quarter ended
Media Contact:
(949) 453-8080
stephanie@lages.com
Investor Relations Contact:
investors@cytekbio.com
2021 GlobeNewswire, Inc., source
